DeepOncology AI

Company Overview

Snapshot

Founded in February 2018 by Shlomo Kashani, DeepOncology AI operates with 1–10 employees. The company focuses on developing visual detection technology for liver cancer, leveraging artificial intelligence and computer vision. DeepOncology AI ceased operations in October 2021.

Business overview

DeepOncology AI develops technology that utilizes deep learning techniques in radiology and oncology to facilitate clinical cancer research and diagnosis. The company's core product, DeepOn device, addresses the need for automated analysis tools to screen for liver metastases using 3D imaging, aiming for precise tumor characterization and early diagnosis. DeepOncology AI operates within the Health Tech & Life Sciences sector, specifically in Digital Healthcare and Medical Decision Support, serving healthcare providers, hospitals, and clinics globally.

Company Intelligence Q&A

What is DeepOncology AI's primary focus?

DeepOncology AI focuses on developing visual detection technology for liver cancer, integrating oncology, artificial intelligence, and computer vision for clinical cancer research and diagnosis.

When was DeepOncology AI founded?

DeepOncology AI was founded in February 2018.

Who is the founder of DeepOncology AI?

Shlomo Kashani is the founder and Chief Data Scientist of DeepOncology AI.

What is the status of DeepOncology AI?

DeepOncology AI ceased to operate in October 2021.

What technology does DeepOncology AI utilize?

DeepOncology AI utilizes deep learning techniques, artificial intelligence, and computer vision in the fields of radiology and oncology to analyze 3D imaging for liver cancer detection.